Nothing Special   »   [go: up one dir, main page]

CL2004001278A1 - COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN - Google Patents

COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN

Info

Publication number
CL2004001278A1
CL2004001278A1 CL200401278A CL2004001278A CL2004001278A1 CL 2004001278 A1 CL2004001278 A1 CL 2004001278A1 CL 200401278 A CL200401278 A CL 200401278A CL 2004001278 A CL2004001278 A CL 2004001278A CL 2004001278 A1 CL2004001278 A1 CL 2004001278A1
Authority
CL
Chile
Prior art keywords
oxybin
fluoruracilo
etopocido
cisplatino
camptotecina
Prior art date
Application number
CL200401278A
Other languages
English (en)
Inventor
Osamu Sugawara Tatsu Nakanishi
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CL2004001278A1 publication Critical patent/CL2004001278A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
CL200401278A 2003-05-26 2004-05-26 COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN CL2004001278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26

Publications (1)

Publication Number Publication Date
CL2004001278A1 true CL2004001278A1 (es) 2005-05-06

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401278A CL2004001278A1 (es) 2003-05-26 2004-05-26 COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN

Country Status (27)

Country Link
US (1) US20070098816A1 (es)
EP (1) EP1626719A1 (es)
JP (1) JP2006526031A (es)
KR (1) KR100938712B1 (es)
CN (2) CN101322707A (es)
AR (1) AR045318A1 (es)
AU (1) AU2004241873C1 (es)
BR (1) BRPI0410959A (es)
CA (4) CA2527191A1 (es)
CL (1) CL2004001278A1 (es)
CO (1) CO5660262A2 (es)
CR (1) CR8163A (es)
CU (1) CU23490B7 (es)
EC (1) ECSP056253A (es)
IL (1) IL171941A0 (es)
ME (1) MEP32308A (es)
MX (1) MXPA05012345A (es)
NO (1) NO20055417L (es)
NZ (1) NZ543591A (es)
PE (1) PE20050206A1 (es)
RS (1) RS20050884A (es)
RU (1) RU2322971C2 (es)
TW (1) TW200505424A (es)
UA (1) UA81499C2 (es)
UY (1) UY28330A1 (es)
WO (1) WO2004103369A1 (es)
ZA (1) ZA200509515B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
ATE471740T1 (de) 2003-09-25 2010-07-15 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
EP1861094A4 (en) * 2005-03-11 2014-06-11 Univ Colorado HISTONDEACETYLASE INHIBITORS SENSITIZE CANCER CELLS FOR EPIDERMAL GROWTH FACTOR INHIBITORS
JP5744376B2 (ja) 2005-03-22 2015-07-08 プレジデント アンド フェローズ オブ ハーバード カレッジ タンパク質分解障害の治療
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
CN103739515B (zh) 2006-02-14 2015-11-25 哈佛大学的校长及成员们 组蛋白去乙酰化酶抑制剂
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
CN101484156B (zh) 2006-05-03 2015-11-25 哈佛大学校长及研究员协会 组蛋白脱乙酰基酶和微管蛋白脱乙酰基酶抑制剂
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
WO2008082856A1 (en) * 2006-12-26 2008-07-10 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
WO2010011296A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PE20141062A1 (es) * 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
EP2395972A4 (en) * 2009-02-11 2014-02-12 Liangping Yu PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME
BRPI1009919A2 (pt) * 2009-05-01 2017-03-28 Oncozyme Pharma Inc combinações de pentamidina para tratamento de câncer.
BRPI1010884A2 (pt) * 2009-06-08 2016-03-15 Gilead Sciences Inc composto inibidores hdac de alcanoilamino benzamida anilina
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
ES2627820T3 (es) 2011-09-13 2017-07-31 Pharmacyclics, Inc. Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
EP3733185B1 (en) * 2011-09-30 2022-12-07 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
EP2751097A2 (en) 2011-09-30 2014-07-09 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of atr kinase
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
AU2014249050B2 (en) 2013-03-12 2017-10-05 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
EA201592012A8 (ru) * 2014-02-21 2018-10-31 Общество С Ограниченной Ответственностью "Биолаб 612" Применение флагеллина для улучшенной химиотерапии
AU2015318111A1 (en) 2014-09-17 2017-04-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US6469058B1 (en) * 1998-09-25 2002-10-22 Warner-Lambert Company Chemotherapy of cancer with actyldinaline in combination with gemcitabine capecitabine or cisplatin
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
HUP0203153A3 (en) * 1999-11-10 2005-01-28 Warner Lambert Co Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
PE20050206A1 (es) 2005-03-26
CA2527191A1 (en) 2004-12-02
TW200505424A (en) 2005-02-16
MXPA05012345A (es) 2006-02-08
BRPI0410959A (pt) 2006-07-04
JP2006526031A (ja) 2006-11-16
UA81499C2 (en) 2008-01-10
NZ543591A (en) 2009-09-25
KR100938712B1 (ko) 2010-01-25
ECSP056253A (es) 2006-10-25
NO20055417D0 (no) 2005-11-16
MEP32308A (en) 2010-10-10
AU2004241873B2 (en) 2008-05-08
RU2322971C2 (ru) 2008-04-27
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
US20070098816A1 (en) 2007-05-03
CN1794991A (zh) 2006-06-28
UY28330A1 (es) 2004-12-31
CA2634765A1 (en) 2004-12-02
IL171941A0 (en) 2006-04-10
CA2634709A1 (en) 2004-12-02
RU2005140570A (ru) 2006-06-10
WO2004103369A1 (en) 2004-12-02
RS20050884A (en) 2008-04-04
ZA200509515B (en) 2006-07-26
AU2004241873C1 (en) 2009-01-22
AU2004241873B8 (en) 2008-05-29
EP1626719A1 (en) 2006-02-22
AU2004241873A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02
CU23490B7 (es) 2010-02-23
CO5660262A2 (es) 2006-07-31
KR20060009371A (ko) 2006-01-31
AR045318A1 (es) 2005-10-26
NO20055417L (no) 2005-12-19

Similar Documents

Publication Publication Date Title
CL2004001278A1 (es) COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN
CY2017029I1 (el) ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
DK2207786T3 (da) 2´-Fluor-2´-deoxytetrahydrouridiner som cytidindeaminasehæmmere
CL2007001325A1 (es) Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades.
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
NL1030486A1 (nl) Dibenzylamineverbindingen en derivaten.
BRPI0608885A2 (pt) composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica
CL2007003565A1 (es) Compuestos derivados de piperidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion vih.
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
BRPI0511900A (pt) composições farmacêuticas
DE60334165D1 (de) Härtbare Zusammensetzung
BRPI0721213A2 (pt) "regime de dosagem de inibidores da comt"
NO20051688D0 (no) Farmasoytiske blandinger som har en modifisert baerer
NL2000527A1 (nl) Dibenzylamine-verbindingen en -derivaten.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
DK1587478T3 (da) Farmaceutisk sammensætning
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
PT1560826E (pt) Compostos piridopirimidinona, seus processos de preparacao e composicoes farmaceuticas que os contem